BriaCell Files Patent Application for Novel Therapeutics for Cancer
April 27 2020 - 5:30AM
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, announces that it has filed a provisional patent
application with the U.S. Patent and Trademark Office (USPTO)
outlining the development and use of novel therapeutics (i.e.
multi-specific binding reagents) that activate immune cells to
selectively destroy the cancer cells or to selectively block cancer
cells from inactivating immune cells.
The patent application, entitled “METHODS FOR
INDUCING AND ENHANCING ANTI-CANCER IMMUNE RESPONSES USING NOVEL
MOLECULAR CONSTRUCTS”, outlines the development and use of
multi-specific binding reagents that simultaneously bind to an
immune cell and a cancer cell, or just to a cancer cell, and
activate the immune system against the cancer cells. The novel
binding reagents are designed to act, among others, as potent
immune cell activators/immune checkpoint inhibitors without the
toxicity of current checkpoint inhibitors. The expected effect is a
highly targeted therapy envisioned to selectively destroy cancer
cells without affecting normal (non-cancerous) cells. This may mean
less severe side effects for the treated cancer patients compared
to alternative therapies. The Company cautions that these novel
therapeutics are still under early-stage research and development
and is not making any express or implied claims as to their success
in cancer treatment or commercial viability. The patent application
seeks protection for, among others, the design of new therapeutics
and methods for their use.
The Company’s scientific experts have read and
approved the scientific disclosures contained in the press
release.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024